or.
Simvastatin: (Moderate) Use caution if ribociclib is coadministered with simvastatin, as the systemic exposure of simvastatin may increase resulting in simvastatin-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and simvastatin is a CYP3A4 substrate.
Simvastatin; Sitagliptin: (Moderate) Use caution if ribociclib is coadministered with simvastatin, as the systemic exposure of simvastatin may increase resulting in simvastatin-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and simvastatin is a CYP3A4 substrate.
Sirolimus: (Moderate) Use caution if coadministration of ribociclib with sirolimus is necessary, as the systemic exposure of sirolimus may be increased resulting in an increase in sirolimus-related adverse reactions. Monitor sirolimus trough concentrations and adjust the dose if necessary. Ribociclib is a moderate CYP3A4 inhibitor and sirolimus is a CYP3A4 substrate with a narrow therapeutic window.
Sofosbuvir; Velpatasvir: (Moderate) Use caution if ribociclib is coadministered with velpatasvir, as the systemic exposure of velpatasvir may increase resulting in velpatasvir-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and velpatasvir is a CYP3A4 substrate.
Sofosbuvir; Velpatasvir; Voxilaprevir: (Moderate) Use caution if ribociclib is coadministered with velpatasvir, as the systemic exposure of velpatasvir may increase resulting in velpatasvir-related adverse reactions. Ribociclib is a moderate CYP3A4 inhibitor and velpatasvir is a CYP3A4 substrate.
Solifenacin: (Major) Avoid coadministration of ribociclib with solifenacin due to an increased risk for QT prolongation and torsade de pointes (TdP). Systemic exposure of solifenacin may also be increased resulting in increase in treatment-related adverse reactions. Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Solifenacin has been associated with dose-dependent prolongation of the QT interval; TdP has been reported with postmarketing use, although causality was not determined. Concomitant use may increase the risk for QT prolongation. Ribociclib is also a moderate CYP3A4 inhibitor and solifenacin is a CYP3A4 substrate.
Sonidegib: (Major) Avoid the concomitant use of sonidegib and ribociclib; sonidegib exposure may be significantly increased resulting in increased risk of adverse events, particularly musculoskeletal toxicity. Ribociclib is a CYP3A4 inhibitor in vitro at clinically relevant concentrations and sonidegib is a CYP3A4 substrate. Physiologic-based pharmacokinetics (PBPK) simulations indicate that the sonidegib geometric mean steady-state AUC would increase 1.8-fold in cancer patients who received 14 days of sonidegib in combination with a moderate CYP3A inhibitor. Additionally, the PBPK model predicts that the sonidegib geometric mean steady-state AUC would increase 2.8-fold in cancer patients who received sonidegib in combination with a moderate CYP3A inhibitor for 4 months.
Sorafenib: (Major) Avoid coadministration of ribociclib with sorafenib due to an increased risk for QT prolongation and torsade de pointes (TdP). Ribociclib has been shown to prolong the QT interval in a concentration-dependent manner. Sorafenib has also been associated with QT prolongation. Concomitant use may increase the risk for QT prolongation.
Sotalol: (Major) Avoid coadministration of ribociclib with sotalol due to an increased risk fo |
